REXO5

Across TCGA pan-cancer cohorts, REXO5 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated REXO5 data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher REXO5 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated REXO5 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where REXO5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.785	0.169	<.001	17	view →
HNSC	DFS	Median	III,IV	0.904	0.677	.008	13	view →
PDAC	DFS	Quartile	III,IV	0.402	0.819	.027	6	view →
GBM	DFS	Median	All	0.438	0.289	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

REXO5–LUAD (DFS)

Open the LUAD breakdown →